Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock December 17, 2015
RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs December 8, 2015
Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689 September 29, 2015
Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia September 2, 2015
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia August 24, 2015
Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR-125844 July 30, 2015
Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder July 24, 2015